Contact
searchSearch
HMP Global
Login

Multiple Myeloma Excellence Forum

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Luciano Costa, MD
Conference Coverage
Teclistamab Plus Daratumumab Demonstrates Significant Survival Benefit for R/R Multiple Myeloma: MajesTEC-3 Trial
01/30/2026
Luciano J. Costa
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported...
01/30/2026
Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Evaluating Infection Patterns Among Patients With Multiple Myeloma Receiving BCMA-Targeting CAR T-Cell Therapy
01/26/2026
Bilal Abid, MD, MS, FACP, MRCP, FRCP
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP,...
01/26/2026
Oncology
Ira Zackon, MD
Conference Coverage
Real-World Analysis Shows Rapid Uptake of Bispecific Antibodies in Community Settings for Multiple Myeloma Treatment
01/22/2026
Ira Zackon, MD
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results...
01/22/2026
Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Conference Coverage
KTX1001 Monotherapy Shows Clinical Activity and Manageable Safety for R/R Myeloma
01/22/2026
Saad Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP,...
01/22/2026
Oncology
Ola Landgren, MD, PhD
Conference Coverage
Daratumumab Plus Teclistamab Demonstrates Favorable Safety and Efficacy for Smoldering Multiple Myeloma: REVIVE Study
01/22/2026
C. Ola Landgren, MD, PhD
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared...
01/22/2026
Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Conference Coverage
Teclistamab Plus Talquetamab Shows Deep and Durable Responses for Extramedullary Multiple Myeloma: RedirecTT-1
01/08/2026
Saad Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP,...
01/08/2026
Oncology
Joseph Mikhael, MD
Conference Coverage
Optimizing Sequencing of CAR T-Cell and Bispecific Therapies to Improve Multiple Myeloma Outcomes
01/05/2026
Joseph Mikhael, MD, MEd, FRCPC
Joseph Mikhael, MD, explains the importance of strategic sequencing and safety optimization for multiple myeloma immunotherapies.
Joseph Mikhael, MD, explains the importance of strategic sequencing and safety optimization for multiple myeloma immunotherapies.
Joseph Mikhael, MD, explains the...
01/05/2026
Oncology
Robert Orlowski, MD, PhD
Conference Coverage
Linvoseltamab Demonstrates Deep, Durable Responses as Frontline Myeloma Therapy: LINKER-MM4 Trial
12/17/2025
Robert Orlowski, MD, PhD
At the 2025 ASH Annual Meeting & Exposition, Robert Orlowski, MD, PhD, shares results from the LINKER-MM4 trial which evaluated linvoseltamab for newly diagnosed multiple myeloma.
At the 2025 ASH Annual Meeting & Exposition, Robert Orlowski, MD, PhD, shares results from the LINKER-MM4 trial which evaluated linvoseltamab for newly diagnosed multiple myeloma.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Ran Reshef, MD, MSc
Conference Coverage
Relationship of Cilta-Cel Dose to PFS Outcomes for Patients With R/R Multiple Myeloma: Real-World Analysis
12/08/2025
Ran Reshef, MD, MSc
Higher cell doses of ciltacabtagene autoleucel were associated with improved progression-free survival without added toxicity, according to results from a real-world analysis presented by Ran Reshef, MD, MSc, at the 2025 ASH Annual Meeting &...
Higher cell doses of ciltacabtagene autoleucel were associated with improved progression-free survival without added toxicity, according to results from a real-world analysis presented by Ran Reshef, MD, MSc, at the 2025 ASH Annual Meeting &...
Higher cell doses of...
12/08/2025
Oncology
Mitul Gandhi, MD
Conference Coverage
Daratumumab Added to Lenalidomide Maintenance Therapy Following Transplant Improves Depth and Durability of MRD Response for MM: AURIGA Study
12/07/2025
Mitul Gandhi, MD
Daratumumab plus lenalidomide maintenance therapy following ASCT improved MRD-negative conversion and durability among newly diagnosed multiple myeloma patients, according to data presented at 2025 ASH Annual Meeting & Exposition.
Daratumumab plus lenalidomide maintenance therapy following ASCT improved MRD-negative conversion and durability among newly diagnosed multiple myeloma patients, according to data presented at 2025 ASH Annual Meeting & Exposition.
Daratumumab plus lenalidomide...
12/07/2025
Oncology

Section Editor

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use